MLN4924, also known as pevonedistat, is the first-in-class inhibitor of NEDD8-activating enzyme, which blocks the entire neddylation modification of proteins. Previous preclinical studies and current clinical trials have been exclusively focused on its anticancer property. Unexpectedly, we show here, to our knowledge for the first time, that MLN4924, when applied at nanomolar concentrations, significantly stimulates in vitro tumor sphere formation and in vivo tumorigenesis and differentiation of human cancer cells and mouse embryonic stem cells. These stimulatory effects are attributable to (i) c-MYC accumulation via blocking its degradation and (ii) continued activation of EGFR (epidermal growth factor receptor) and its downstream pathways, including PI3K/AKT/mammalian target of rapamycin and RAS/RAF/MEK/ERK, via inducing EGFR dimerization. Finally, MLN4924 accelerates EGF-mediated skin wound healing in mouse and stimulates cell migration in an in vitro culture setting. Taking these data together, our study reveals that neddylation modification could regulate stem cell proliferation and differentiation and that a low dose of MLN4924 might have a therapeutic value for stem cell therapy and tissue regeneration.
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MLN4924 | neddylation | EGFR | stem cell | wound healing I n cells, homeostasis is reached by a fine balance between the rates of protein synthesis and degradation. The process of protein degradation by the ubiquitin-proteasome system (UPS) involves two sequential steps: (i) ubiquitylation catalyzed by the ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), and a ubiquitin ligase (E3) and (ii) degradation catalyzed by 26S proteasome (1) . Abnormal UPS activity abrogates the homeostasis and is associated with many human diseases, including cancer (2, 3) . Bortezomib, the first Food and Drug Administration-approved proteasome inhibitor for the treatment of multiple myeloma and mantle cell lymphoma (4), possesses significant cytotoxicity against normal cells due to its universal inhibition of the UPS (5) . This stimulated an intensive search for inhibitors targeting the enzymes upstream of the proteasome for improved specificity.
Cullin-RING ligases (CRLs), consisting of scaffold cullins, adaptor proteins, substrate-recognizing receptors, and RING finger proteins, are the largest family of E3 ubiquitin ligases and are responsible for the ubiquitylation of about 20% of all cellular proteins (6, 7) . The activity of CRLs requires neddylation of the cullin proteins (8, 9) , a ubiquitylation-like process, which is sequentially catalyzed by three enzymes: a NEDD8-activating enzyme (NAE or E1), NEDD8-conjugating enzyme (E2), and NEDD8 ligase (E3). Abnormal elevation of CRL activity has been found in multiple human cancers, which makes them favorable targets for cancer treatment (10, 11) .
MLN4924 was descried in 2009 as the first-in-class NAE inhibitor exclusively in the application for cancer treatment by inactivation of CRLs via blockage of cullin neddylation (7) . Since the initial report, more than 150 papers (by PubMed search) were published to show its preclinical anticancer activity, either acting alone or in combination with current chemotherapy and/or radiation (6, 11) . One of the seven clinical trials of MLN4924 (NCT00911066) was published recently, concluding a modest effect of MLN4924 against acute myeloid leukemia (AML) (12) .
To further elucidate the role of blocking neddylation in cancer treatment, we thought to study the effect of MLN4924 on cancer stem cells (CSCs) or tumor-initiating cells (TICs), a small group of tumor cells with stem cell properties that have been claimed to be responsible for cancer initiation and relapse (13) . Meanwhile, a recent study showed that pharmacological inactivation of SKP2 SCF (SKP1-Cullins-F-box proteins) E3 ubiquitin ligase (also known as CRL1) by a small molecule inhibitor, compound 25, could restrict CSC traits and cancer progression in prostate cancer (14) .
To our utter surprise, we found that at low drug concentrations (30-100 nM), MLN4924 stimulates in vitro tumor sphere (TS) formation and in vivo tumorigenesis of both cancer cells and embryonic stem cells. Mechanistic studies revealed the involvement of accumulation of c-MYC, and dimerization and activation of EGFR (epidermal growth factor receptor). We also found that MLN4924 could accelerate the process of EGFinduced skin wound healing in mouse and cell migration in an in vitro culture setting. Thus, MLN4924, when applied at low Significance MLN4924, a potent small-molecule inhibitor of NEDD8-activating enzyme, blocks cullin-RING ligase activity through inhibiting cullin neddylation. MLN4924 is widely used in both preclinical and clinical settings for an anticancer application. We report here an unexpected finding: MLN4924 at nanomolar concentration stimulates stem cell proliferation, self-renewal, and differentiation in both tumor and normal stem cell models and promotes skin wound healing in a mouse model and cell migration in vitro. Mechanistic studies revealed that MLN4924 causes c-MYC accumulation and promotes EGFR (epidermal growth factor receptor) dimerization to activate the EGFR signaling pathway. Our study raises a concern in anticancer application of MLN4924, but at the same time provides an opportunity for future development of MLN4924 as an agent for stem cell therapy and tissue regeneration.
concentrations, may have potential utility in the field of stem cell therapy and tissue regeneration.
Results
Bipolar Effects of MLN4924 on Proliferation of Cancer Cells. Suppression of cancer cell growth by MLN4924 has been welldocumented in the literature (for a review, see ref. 11). Indeed, we found a dose-dependent growth inhibition in multiple human cancer cell lines, including H1299 (lung cancer), MCF7 and SUM159 (breast cancer), and HCT116 (colorectal cancer), when cultured in the media containing 10% (vol/vol) or 1% serum ( Fig. S1 A and B) . Unexpectedly, when cultured in serum-free medium, we observed various degrees of dose-dependent growth stimulation at low MLN4924 concentrations (30-300 nM) in H1299 [maximum effective concentration (EC max ), 0.1 μM, P < 0.0001 (Fig. S1A) ], HCT116 (EC max , 0.3 μM, P < 0.0001) (Fig.  S1B ), MCF7 (EC max , 0.1 μM, P = 0.0001) (Fig. S1B) , and SUM159 (EC max , 0.1 μM, P = 0.0098) (Fig. S1B ) cells, followed by growth suppression at higher concentrations. We confirmed via trypan blue exclusion assay that the number of living cells was indeed significantly increased following treatment with a low dose of MLN4924 under serum-free conditions (Fig. S1C) (P < 0.0001). Collectively, we uncovered the bipolar effects of MLN4924 on cell proliferation, both stimulatory and inhibitory, on cancer cells depending on serum and drug concentrations. We then focused our study on the growth-stimulating effect of MLN4924.
MLN4924 Stimulates TS Formation in Multiple Cancer Cell Lines. The observation that MLN4924 at low concentrations stimulated cell growth under serum-starved conditions triggered us to test whether MLN4924 would promote TS formation, an assay widely used to study the stem cell potential in a serum-free suspension culture (15) . We first tested H1299 nonsmall cell lung cancer (NSCLC) cells that formed typically spherical TSs in standard conditioned TS medium (16) . We found a significant dosedependent stimulation by MLN4924 on TS formation with an EC max of 100 nM, followed by a dose-dependent inhibition of TS formation, with 1 μM MLN4924 completely disrupting TS formation (Fig. 1A) . To quantify, we used our recently developed Standardized Sphere Score (SSS) (16) as the assessment parameter and found that 0.1 μM MLN4924 induced a greater than 30-fold increase in SSS in H1299 cells (Fig. 1B) (P < 0.0001). The stimulation was also time dependent, despite the fact that no medium change or growth factor replenishment was performed throughout the entire assay period of up to 16 d (Fig. 1C) (P = 0.013 at 4 d and P < 0.0001 at 8, 12, and 16 d). It is worth noting that although TSs did not appear to grow bigger in 0.1-μM MLN4924-treated groups (Fig. 1A ) from the 12-d to the 16-d time points, a more than twofold increase in SSS was observed (Fig.  1C ) (P = 0.0077), suggesting that those TSs with the largest size might have reached the maximal growth capacity, possibly as a result of central necrosis (17) , whereas smaller TSs continued to grow, giving rise to a higher SSS at the later time point.
To further confirm the stimulatory effect of MLN4924 on TS formation, we harvested TSs cultured in MLN4924 (0.1 μM), along with the vehicle control, and performed Ki67 staining on TS sections (Fig. 1D) . We quantified the result by dividing the number of Ki67 + cells by the area of each respective section ( Fig.  S1D ) and found a significantly higher ratio of Ki67 + cells in TSs cultured with 0.1 μM MLN4924 (Fig. S1E) (P < 0.0001).
Given that MLN4924 stimulated proliferation of monolayercultured cancer cells in the absence of any serum or growth factors ( Fig. S1 A and B) , we next determined whether MLN4924 could stimulate TS formation under EGF-free TS medium. Although, as expected, TS formation was significantly impaired without EGF supplementation, MLN4924 alone was indeed capable of inducing TS formation in H1299 cells in TS medium without EGF supplementation (Fig. 1E , blue bars) (P < 0.0001). The same stimulating effect, to various extents, was also observed in other human cancer cell lines that form typical TSs in our conditioned TS medium, including H125 (NSCLC), MCF7/ SUM159 (breast cancer), and PC3 (prostate cancer) (Fig. S1F) .
We next directly compared the TS-stimulating activity between MLN4924 and EGF given at the standard concentration (20 ng/mL) or much higher concentration (1,000 ng/mL). As expected, addition of standard as well as high concentrations of EGF significantly promoted TS formation (Fig. 1E , blue solid bars versus black solid bars, P = 0.0218; blue solid bars versus red solid bars, P = 0.0252) but in an EGF concentration-independent manner (Fig. 1E) , suggesting that EGF was probably already saturated in the standard condition. Surprisingly, MLN4924 alone at 0.1 μM remarkably stimulated TS formation with about 10-fold more effectiveness than EGF (Fig. 1E) (P < 0.0001). More importantly, a combination of either a standard or high concentration of EGF did not seem to further enhance MLN4924 activity (Fig. 1E) . Taken together, it appears that MLN4924 at low concentrations is an effective stimulator of TS formation with an activity that is much greater than EGF.
MLN4924 Stimulates Self-Renewal and Increases the Level of Stem
Cell Marker CD44. Self-renewal is one of the key features of stem cells (13) . The capability of TSs being serially passaged is indicative of self-renewal (18) . We next determined the effect of MLN4924 on stem cell self-renewal. A single-cell suspension was prepared by enzymatic and mechanic disassociation of H1299 TS formed in 0.1 μM MLN4924-containing culture (first generation of TSs) and replated for the formation of the next generation of TSs in the presence of vehicle control or indicated concentrations of MLN4924. The results showed that H1299 cells that originated from TSs cultured in MLN4924 were capable of forming new TSs, indicating the self-renewal ability of these cells (Fig. 1F , red frame). Interestingly, EC max of secondary and tertiary TSs shifted from 0.1 μM to 0.3 μM (Fig. 1F and Fig. S1G, red) . A possible explanation is that tumor cells became more resistant to the growth inhibitory effect of MLN4924 after being cultured for primary TS formation in MLN4924. In addition, maximal secondary and tertiary SSSs in 0.1 μM MLN4924 culture were significantly larger than that of primary SSSs (Fig. S1G, red) , suggesting a higher percentage of CSCs in TSs than in monolayer culture, which is consistent with a previous report (19) .
CD44, a cell surface glycoprotein functioning as a receptor for hyaluronic acid (HA), is involved in cell-to-cell interactions, cell adhesion, and migration (20) . Many normal stem cells express CD44, including ESCs (21) . CD44 has also been established as a CSC marker in multiple human cancers (22) , including lung cancer (23) . We found that H1299 TSs cultured in 0.1 μM MLN4924 expressed significantly higher levels of CD44 compared with the TSs cultured in vehicle control (Fig. 1G) , whereas MLN4924 had no effect on CD44 expression when cells were cultured in monolayer (Fig. S1H) . Thus, MLN4924 appears to maintain stem cell selfrenewal and enrich the CSC population in TS culture.
MLN4924 Stimulated in Vivo Tumorigenesis. We next extended our in vitro observations to an in vivo xenograft tumor model by determining whether MLN4924 at a low concentration would stimulate tumor growth in nude mice. We designed and performed two experiments. In the first experiment, we compared the in vivo tumorigenicity of cells that originated from TS cultured in 0.1 μM MLN4924 (with a higher proliferation index) ( Fig. 1D and Fig. S1 D and E) versus TSs cultured in vehicle control by subcutaneous implantation in the right and left flank region, respectively, of BALB/c background SCID NCr immunodeficient mice (Charles River). Unexpectedly, no difference in tumorigenicity was observed ( Fig. S1 I and J), suggesting that without continuous exposure to MLN4924, enhanced proliferation of cancer cells cannot be sustained in vivo. Thus, we suspected that the proliferation-promoting effect of MLN4924 is transient if cells are not continuously exposed to MLN4924.
We, therefore, conducted the second in vivo experiment, in which we mimicked the in vitro setting by subcutaneously implanting unselected H1299 cells from monolayer culture mixed with 0.1 μM MLN4924 or vehicle control in the right or left flank of the same strain of nude mice, respectively. No MLN4924 was given after initial implantation. The results showed that MLN4924 significantly promoted in vivo tumorigenesis of H1299 cells with an accelerated growth rate ( 
MLN4924 Stimulates in Vitro Proliferation of mESC and Embryonic
Body Formation. We next determined potential effects of MLN4924 on the proliferation of normal stem cells using mouse embryonic stem cells (mESCs) as a model. In the feeder-free mESC culturing system [supplemented with leukemia inhibitory factor (LIF) to maintain an undifferentiated state of mESC] (24), a bipolar effect of MLN4924 on proliferation was again observed. Significant stimulation of proliferation was observed at the dose range of 0.1∼3 μM (EC max at 24 h, 3 μM, P = 0.0034; EC max at 48 h, 1 μM, P = 0.0041), followed by growth suppression at higher concentrations ( Fig. 2A) . We then plated mESCs at clonal density in an MEF-feeder mESC culturing system to test if MLN4924 could stimulate colony formation under undifferentiated status. Alkaline phosphatase (AP) staining was used to visualize undifferentiated mESC colonies. MLN4924 at a low concentration (0.1 μM) stimulated but at high concentration (1 μM) inhibited colony growth (Fig. 2B and Fig.  S2A ) (P = 0.0326). No significant effect on the number of colonies was observed.
We further tested whether MLN4924 would affect mESC differentiation. We plated mESCs in feeder-free culture supplemented with or without LIF. The proliferation of mESCs was measured by ATPLite assay. Undifferentiated and differentiated colonies were assessed by AP staining. The results showed that MLN4924 exhibited a significant stimulatory effect on mESC proliferation under both differentiating and undifferentiating conditions (Fig. 2C) (P < 0.0001 and P = 0.0213, respectively).
In suspension culture, mESCs can proliferate to form embryonic body (EB) with a spherical 3D structure (25) . We next determined the effect of MLN4924 on mESC proliferation in suspension culture supplemented with LIF in the following three conditions: (i) serum-free but supplemented with 20 ng/mL EGF, (ii) 3% (vol/vol) serum, and (iii) 15% (vol/vol) serum (standard condition). The results showed that 0.1 μM MLN4924 significantly stimulated EB formation under the conditions of serumfree ( Fig. 2D and Fig. S2B ) (EC max , 0.3 μM, P < 0.0001) or 3% (vol/vol) FBS ( Fig. 2E and Fig. S2B ) (EC max , 0.1 μM, P = 0.0004), but not 15% (vol/vol) FBS ( Fig. 2E and Fig. S2B ).
MLN4924 Stimulates Teratoma Formation in Vivo.
The subcutaneously implanted mESCs in immunodeficient mice can proliferate and differentiate to form teratoma consisting of multiple tissues from all germ layers (26) . We determined whether MLN4924 could promote in vivo mESC proliferation/differentiation by stimulating teratoma formation in nude mice. Similar to our second H1299 xenograft model, we injected matrigel-mixed single cell suspension of mESCs supplemented with 0.1 μM MLN4924 or the vehicle control subcutaneously in the right or left flank of nude mice, respectively. Again, no MLN4924 was administered after implantation. The results showed that MLN4924 significantly stimulated teratoma formation (Fig. 2F) , as evidenced by accelerated tumor growth ( To show the tumors are indeed teratoma in nature, we sectioned and H&E-stained the tumors and found various tissues derived from all three germ layers, including (i) neuronal rosettes (ectoderm), (ii) squamous epithelium (ectoderm), (iii) cartilage (mesoderm), (iv) striated muscle (mesoderm), (v) gut-like structure lined with mucinous epithelium (endoderm), and (vi) glands (endoderm) (Fig. S2C) , confirming that MLN4924 stimulated in vivo proliferation and differentiation of mESCs.
TS Stimulatory Effect of MLN4924 Is Mediated in Part by the c-MYC/ FBXW7
Axis. Given that CRL-mediated ubiquitylation and degradation of proteins can be blocked by MLN4924 (6, 11), we hypothesized that MLN4924 might stimulate TS formation by blocking the degradation of oncoproteins or stemness factors that were substrates of CRL. c-MYC is one of the four Yamanaka factors (OCT3/4, SOX2, c-MYC, and KLF4) that are capable of reprogramming fibroblasts to induced pluripotent stem cells (27) . C-Myc itself has been shown to play a significant role in selfrenewal of stem cells (28) . Because it is well-known that c-MYC is subjected to ubiquitylation and degradation by two SCF E3 ubiquitin ligases, SCF FBXW7 (29) and SCF SKP2 (30), we determined whether MLN4924 can cause accumulation of c-MYC by inactivation of cullin neddylation (7) . As expected, we observed a dose-dependent increase of c-MYC upon MLN4924 treatment in multiple cell lines (Fig. 3A) . We next determined whether c-MYC accumulation was causally related to the TS-stimulating effect of MLN4924. We silenced c-MYC (Fig. 3B ) and did observe a significant reduction, but not complete abrogation, of MLN4924-induced TS formation (Fig. 3C and Fig. S3A ) (P = 0.003). We also measured the effects of MLN4924 on the protein levels of the other three Yamanaka factors-KLF4, SOX2, and OCT4-and found that the effect was protein-as well as cell line-dependent. Either induction or repression, or even no effect, was observed among the three cancer cell lines tested (Fig. S3B) , thus excluding their potential involvement.
Given that FBXW7 binds to c-MYC and promotes its degradation (29), we further determined the role of FBXW7 in MLN4924-induced TS formation by using a pair of isogenic HCT116 FBXW7 +/+ and HCT116 FBXW7 −/− cell lines (31) . We first found that although the basal level of c-MYC was higher in null cells, MLN4924 treatment caused a dose-dependent c-MYC accumulation in wild type but not in null cells, even though SCF SKP2 was unaffected (Fig. 3D) , indicating that FBXW7 knockout could completely abolish c-MYC accumulation upon MLN4924 treatment. We then tested the response of the two isogenic lines to MLN4924 by TS formation assay and found that MLN4924 could still stimulate TS formation in FBXW7-null cells, although to a less extent than wild-type cells (Fig. 3E and Fig. S3C) . Thus, the TS stimulatory effect of MLN4924 is partially mediated by the c-MYC/FBXW7 axis, whereas other signaling pathways may also be involved.
MLN4924 Activates EGFR and Its Downstream Signaling Pathways.
Given that (i) MLN4924 stimulated the TS formation in conditioned culture medium without any supplement of growth factors (EGF and bFGF) and (ii) MLN4924 increased the expression of CD44 in TS, a receptor similar and closely related to EGFR in cancer cells (32), we hypothesized that MLN4924 might also act through activation of growth factor pathways, particularly the EGFR signaling pathways.
We first found that pretreatment with MLN4924 could enhance EGF-stimulated EGFR phosphorylation and elevate the expression of total EGFR (to a less extent) in H1299 and HCT116 cells (Fig. S4A) . We next measured a time-dependent (a period of 2-256 min) activation of EGFR and its downstream signaling pathways by EGF, MLN4924 alone, or the combination of both (with MLN4924 pretreatment for 24 h). Compared with EGF alone, the combination of EGF-MLN4924 caused a greater activation of EGFR itself on Tyr845 and Tyr1173, IRS1 on Ser636/639, AKT on Thr308/Ser473, S6K on Thr389, RAF on Ser259, and ERK on Thr202/Thr204 (Fig. 4A) . However, within this shorter exposure time, MLN4924 alone had minor, if any, effect on the activation of EGFR and its downstream pathways (Fig. 4A) . Taken together, it appeared that 0.1 μM MLN4924 enhanced and prolonged EGF-induced activation of EGFR and its major downstream signaling pathways, PI3K/AKT/mTOR (mammalian target of rapamycin) and RAS/RAF/ERK, that are closely related to cell proliferation.
We next tested the dose-dependent (0.03, 0.1, and 0.3 μM) effect of MLN4924 alone on the activation of EGFR and its downstream targets after prolonged exposure (24 h). We included three cancer cell lines (H1299, HCT116, and U87) to exclude the possibility of any cell line-dependent effect. The results showed that MLN4924 itself was capable of causing EGFR autophosphorylation at Tyr1173 (U87) and subsequent phosphorylation at Tyr845 (all three cell lines), which was crucial for EGFR kinase activity (33) (Fig. 4B) . Dose-dependent increases in AKT phosphorylation at both Thr308 (H1299 and HCT116) and Ser473, and dose-dependent increases in ERK phosphorylation levels was also observed in all three cell lines (Fig. 4B) . These results indicated that MLN4924 alone could activate EGFR and its downstream AKT/ERK signaling pathways.
We then determined the effect of MLN4924 on EGF-induced EGFR turnover using CHX (cycloheximide) to block new EGFR synthesis and found that within a time frame of 5-45 min of EGF stimulation, MLN4924 caused a moderate inhibition of EGFR degradation, as evidenced by a moderate increase in EGFR levels, along with a significantly enhanced phosphorylation of EGFR, AKT, and ERK at the 5-15-min time points (Fig. S4B) .
Effect of the von Hippel-Lindau/HIF1 Axis on MLN4924-Induced Sphere Formation. A previous study reported that the VHL (von Hippel-Lindau)/HIF1α oxygen-sensing axis is implicated in the EGFR internalization process, with HIF1 acting as an inhibitor of EGFR endocytosis (34) . We, therefore, measured the effect of MLN4924 on the levels of these two proteins in lung and colon cancer cells. We found that MLN4924, when acting alone or in combination with EGF, had minimal, if any, effect on the levels of VHL (Fig. S4 C and D) , excluding the involvement of VHL. Our previous study showed that MLN4924 caused accumulation of HIF1α, a well-established substrate of CRL2 in multiple lines of human cancer cells, including HCT116 cells (35) . We confirmed that MLN4924 also caused a dose-dependent accumulation of HIF1α in H1299 cells when cultured in either 10% (vol/vol) or 0% serum (Fig. S4E) . We then used an siRNA-based knockdown approach to determine if HIF1α plays any role in MLN4924-induced sphere stimulation. We predicted that HIF1α knockdown would reduce sphere formation if HIF1 blocks EGFR endocytosis to prolong EGFR signals in our assay condition, as described in the previous study (34) . Unexpectedly, although siHIF1α indeed reduced the level of HIF1α induced by MLN4924 (Fig. 4C) , it caused a ∼twofold increase in sphere formation at the 12 d (red) and 16 d (blue) time points (Fig. 4D) , suggesting that HIF1α played a negative role in MLN4924-induced sphere stimulation under our setting. We, therefore, excluded the possibility that MLN4924 stimulated TS formation by causing HIF1α accumulation. The underlying mechanism of how lower HIF1α level leads to a stimulation of TS formation by MLN4924 requires further investigation.
MLN4924-Induced EGFR Activation Is Independent of c-Casitas
B-Lineage Lymphoma. It was reported that c-Cbl (Casitas Blineage lymphoma) is the E3 ligase for both neddylation and ubiquitylation of EGFR (36, 37) . Upon EGF stimulation, c-Cbl promotes EGFR neddylation to facilitate its ubiquitylation and subsequent endocytosis-based degradation (36) . Given that MLN4924 is a potent neddylation inhibitor (7), it could inactivate neddylation E3 activity of c-Cbl and block endocytic degradation of EGFR. We, therefore, tested the potential involvement of c-Cbl in MLN4924-induced EGFR activation. We hypothesized that if the MLN effect is mediated through c-Cbl, c-Cbl depletion would abrogate it. However, we observed a minimal, if any, effect of c-Cbl knockdown on total levels of EGFR and EGFR downstream signaling pathways (Fig. 5A) . Furthermore, c-Cbl knockdown caused a decrease, rather than an expected increase, in the levels of phosphorylated EGFR and total EGFR and had a minimal effect, if any, on MLN4924-affected EGFR turnover (Fig. S5A) . Thus, MLN4924 manipulation of EGFR appeared to be independent of c-Cbl.
MLN4924 Does Not Bind to EGFR Directly but Induces EGFR Dimerization.
To elucidate the possible mechanisms by which MLN4924 activated the EGFR signaling pathway, we first determined whether MLN4924 could directly bind to EGFR using the cellular thermal shift assay (CETSA) (38), a screening assay designed to monitor drug-target engagement based on the assumption that drug binding could cause a shift in the thermostability of the target. The results showed that MLN4924 did not significantly change the EGFR thermostability (Fig. S5B) , indicating that MLN4924 might not directly bind to EGFR for its action, although we cannot exclude the possibility of a weak binding.
Given that EGFR stabilization and activation can be achieved by its dimerization (39), we next determined whether MLN4924 would trigger EGFR dimerization. Cells were treated with 0.1 μM MLN4924 for 1 h or 24 h or EGF (10 ng/mL served as a positive control), as well as in combination, followed by crosslinking with disuccinimidyl substrate (DSS). The results showed that in both H1299 and HCT116 cells, MLN4924 indeed induced a time-dependent increase in the formation of dimerized EGFR, with combination reaching the highest level of dimerization (Fig. 5B) .
Finally, we used a proximity ligase assay (PLA), also known as proximity ligation immunofluorescence (PLI) (40) , as an independent measure for in situ detection of EGFR dimerization in intact cells. The assay is based upon induced close proximity upon dimerization of two fluorescent-labeled EGFR molecules to trigger unique fluorescent signals (40) . We first confirmed that Myc-or FLAG-tagged EGFR constructs were expressed properly at the individual level (Fig. S5C) and then treated cotransfected cells with MLN4924 or EGF alone or in combination. Indeed, MLN4924 or EGF triggered PLA/PLI signals significantly compared with the vehicle control, with the highest signals seen in combination (Fig. 5C ). Taken together, we have used two independent methods to demonstrate that MLN4924 indeed triggers EGFR dimerization to activate the EGFR signaling pathway.
TS-Stimulating Effect of MLN4924 Requires Activation of EGFR
Signaling Pathways. We next determined, via loss-of-function (kinase inhibitors) and gain-of-function (ectopic EGFR expression) approaches, whether activation of EGFR signaling pathways was causally related to MLN4924-induced TS formation. To reproducibly and quantitatively assess the effect of inhibitors alone (toxicity) or in combination with MLN4924 (rescue), we defined two SSS-based parameters: %SSSi and %SSSr. As explained by the equation (Table S1 ), the higher the %SSSi value, the greater the inhibition of an inhibitor alone on basal level of TS formation, whereas the higher the %SSSr value, the more the blockage of MLN4924-induced TS formation by an inhibitor. Because a high value of %SSSi (which might indicate a high degree of cytotoxicity) of a given inhibitor might interfere with the assessment of its rescue effect on MLN4924, we defined arbitrarily that %SSSr would be more meaningful if %SSSi was less than 0.5 (50% or the dosage of the inhibitor was lower than its IC 50 of TS inhibition effect), despite the fact that we did see a dissociation between the two parameters (Table S1 ). Targeting EGFR. RTKs require their kinase activity to transduce extracellular signals from ligand binding to their intracellular downstream targets. We, therefore, used CI-1033, an irreversible inhibitor (41) , and Erlotinib, a reversible inhibitor (42), of EGFR tyrosine kinase and found that both inhibitors were able to partially block the stimulatory effect of MLN4924 at the concentrations less than the IC 50 dosage (Fig. 6A, and Fig. S6A , P = 0.0074 and P = 0.0181, respectively, and Table S1 ). A higher dose of Erlotinib conferred a better rescue but with a higher %SSSi value (Table S1 ). Targeting PI3K/AKT/mTORC1. We then used several small molecule inhibitors targeting PI3K/AKT/mTOR. LY294002, a classic inhibitor of PI3K (43), significantly blocked the TS-stimulating effect of MLN4924 with a 76% rescue effect (Fig. 6A, Fig. S6B , and Table S1) (P = 0.0083). Likewise, rapamycin, an mTORC1 inhibitor, also showed a 76% rescue effect (Fig. 6A, Fig. S6B , and Table S1) (P = 0.0086). Interestingly, MK2206, a highly selective allosteric AKT inhibitor, which prevented recruitment of AKT to the plasma membrane for activation via binding to the pleckstrin-homology domain to cause conformational change (44), had no rescue effect (Fig. 6C and Fig. S6C ), even when used at a high toxicity dose (Table S1 ) with potent activity in blocking phosphorylation of AKT Ser473 (Fig. S6D) . Moreover, another AKT inhibitor, Perifosine, which blocks the recruitment of AKT to the plasma membrane for activation by PDK1, thus blocking AKT Ser473 phosphorylation (45), had no rescue effect either (Fig.  6D, Fig. S6E , and Table S1 ). On the other hand, however, AKT knockdown by siRNA caused a right shift of the MLN4924-TS stimulation curve (Fig. 6E and Fig. S6F ) (P = 0.0204 at 0.1 μM and P = 0.0006 at 0.3 μM) with a partial rescue activity (Table S1 ). The results suggest that AKT itself, but not its Ser473 phosphorylation or plasma membrane recruitment, is required to mediate MLN4924 action. Taken together, it appeared that the PI3K/AKT/ mTORC1 axis, particularly activation of PI3K and mTORC1 kinases, plays a major role in the MLN4924 TS-stimulating effect. Targeting RAS/RAF/MEK/ERK. We also tested the potential involvement of the RAS/RAF/MEK/ERK pathway using U0126, a selective noncompetitive inhibitor of MEK1/2 (46). U0126 partially Cell lysates were then prepared for Western blot. The band density was quantified using Image J software. Shown are mean ± SEM from three independent experiments. (C) PLA assay to measure EGFR dimerization. EGFRnull CHO cells were cotransfected with plasmids expressing EGFR-MYC and EGFR-FLAG and then seeded in coverslips for treatment with MLN4924 or EGF alone or in combination. The slides were stained with primary antibody, followed by staining using the In Situ-Fluorescence kit. Cell images were acquired, and positive-stained cells were quantified. Shown are mean ± SEM from three independent experiments. blocked the stimulatory effect of MLN4924 on TS formation with a 55.6% rescue effect (Fig. 6F, Fig. S6G , and Table S1) (P = 0.0357), supporting the role of MAPK signaling as a major downstream pathway of EGFR. Activating EGFR. To further validate EGFR involvement, we used a gain-of-function approach by ectopic expression of wild-type EGFR in comparison with a kinase-dead mutant control in EGFR-null Chinese Hamster Ovary (CHO) cells and SW620 cells (human colorectal cancer cells). Because CHO cells do not form TSs whereas SW620 cells can, we, therefore, used ATPLite proliferation assay and TS formation assay to assess the effect of MLN4924, respectively. Indeed, cells expressing wild-type EGFR (Fig. S6H) were more resistant to MLN4924-induced growth suppression in a monolayer culture (Fig. 6G) (P < 0.0001) and were able to form significantly more TSs upon MLN4924 stimulation (Fig. 6H and Fig. S6I ) (P < 0.0001). On the other hand, cells expressing K721M mutant, a point mutation in the ATP pocket of EGFR, which completely inactivates the kinase activity of EGFR (47) , had no such effects (Fig. 6  G and H) . Taken together, these results suggested that the kinase activity of EGFR was required for the growth-stimulating effect of MLN4924.
MLN4924 Promoted EGF-Induced Skin Wound Healing in the Mouse
Model and in Vitro Migration of Immortalized Epithelial Cells. Finally, we determined the potential application of stem cell-stimulating activity of MLN4924 in vivo. Given that EGF has been shown to accelerate the healing process of various types of skin wounds, including massive burns (48), skin loss resulting from trauma or medical procedures, and diabetic ulcers (49) and given that MLN4924 was capable of stimulating proliferation of stem cells by activating EGFR signaling pathways, we used C57BL/6 mice and tested whether MLN4924 could work with EGF synergistically in promoting skin wound healing with the procedures outlined (Fig. S7A) . Because wound contraction after creation of full-thickness skin wound in mice could be problematic for precise assessment of the healing process (50), we used transparent adhesive dermal dressing (3M, Tegaderm) to seal the wound for preventing wound contraction, better observation of the healing process, and prolonged local application of the drug in liquid form. After creating bilateral full-thickness skin wounds as previously described (51), we treated mirroring wounds created on the left and right flank region with either EGF plus vehicle or EGF plus 0.1 μM MLN4924, respectively (n = 11). Dressings were changed, fresh EGF/MLN4924 was applied, and relative areas of wound (RAWs) values were measured and calculated every other day (Fig. 7A) . The results showed that MLN4924 significantly accelerated wounding healing during the early phase (before 6 d), as evidenced by smaller RAW values (P values at day 2, 4, and 6 were 0.0230, 0.0005, and 0.0349, respectively), although it did not seem to affect the total time period required for complete wound closure (12 d) (Fig. 7B) .
We further performed the in vitro scratch assay (52) using BEAS2B cells (a normal epithelial line derived from normal bronchial epithelium and immortalized by infection with a replicationdefective SV40/adenovirus 12) to determine the stimulating effect of MLN4924 on cell migration. We found that migration of BEAS2B cells was promoted by 0.1 μM MLN4924, as well as EGF, but inhibited by 1 μM MLN4924 regardless of EGF. A combination of MLN4924 and EGF induced maximal migration when cells were cultured in 0% (Fig. 7 C and D) or 4% (vol/vol) serum (Fig. S7B) . Collectively, our data showed that MLN4924 indeed promotes cell migration, with a potential to accelerate wound healing. Discussion MLN4924 (pevonedistat) is a potent inhibitor of NAE, thus inactivating the entire process of protein neddylation (7) . MLN4924 showed anticancer activity in various preclinical settings by inducing apoptosis, autophagy, and senescence, as well as overcoming drug resistance and sensitizing chemoradiation (for a review, see refs. 11 and 53). MLN4924 has been evaluated as a single agent in four phase 1 trials in solid tumors and hematological malignancies, and is currently evaluated in phase 1b trials in combination with conventional chemotherapies for solid tumors and AML (11, 54) .
Here, we made a novel and unexpected observation that MLN4924, at low nanomolar concentrations, has significant stimulating activity in promoting cell proliferation and stem cell self-renewal under both in vitro culture and in vivo mice settings, as evidenced by following observations made in (i) monolayer culture of cancer cells and mESCs, (ii) sphere formation of both cancer cells and mouse ESCs, (iii) in vivo tumorigenesis of both cancer cells and mESCs, and (iv) the early phase of wound healing in mouse skin and in vitro migration of immortalized epithelial cells.
Through our mechanistic studies, we propose that this stimulatory effect of MLN4924 could likely be attributable to (i) blockage of degradation of c-MYC, a growth-promoting oncoprotein, and stemness-stimulating factor (Fig. 8A) and (ii) activation of EGFR signaling by inducing dimerization of EGFR (Fig. 8B) . Based on the observations that (i) MLN4924 only caused a minor accumulation of total EGFR, (ii) MLN4924 enhanced and prolonged EGF-induced activation of EGFR signaling pathways, and (iii) prolonged treatment with MLN4924 also activated the EGFR signaling pathway in the absence of EGF, we propose a possible model to explain how MLN4924 would activate EGFR signaling alone or in combination with EGF (Fig. 8) . First, it is well-established that upon addition of EGF to serum-starved cells (in the absence of MLN4924), EGF instantly promotes EGFR dimerization and activation, followed by rapid endocytic degradation of EGFR (55) . Therefore, the activation of EGFR and other downstream targets reaches a peak within minutes, followed by gradual deactivation via endocytic degradation, returning to the basal level at 2 h (Fig. 4A) . Second, upon prolonged exposure of serum-starved cells to a low dose of MLN4924 (in the absence of EGF), a ligand-independent EGFR dimerization occurs (Fig. 5 B and C) through a currently unknown mechanism, leading to accumulation EGFR dimers on the cellular membrane, a known process to cause the activation of EGFR and its downstream signals (39) . Third, in the presence of both EGF and MLN4924, EGFR signaling is again instantly activated by ligand binding with the endocytic degradation of EGFR moderately inhibited possibly by MLN4924-induced EGFR dimerization, leading to sustained EGFR signaling. Interestingly, in our experimental conditions, this process appears to be independent of c-Cbl (Fig. 5A and Fig.  S5A ), an E3 ligase reported to induce EGFR ubiquitylation and neddylation for subsequent endocytosis (36) , and VHL ( Fig. S4 C  and D) , but with HIF1α playing a negative role (Fig. 4 C and D) .
This working model also explains our interesting observation that MLN4924 is much more active than EGF in stimulating TS formation in our system (Fig. 1E) . Given that EGF causes a rapid activation of EGFR, which triggers recycling of activated EGFR for endocytosis, the EGF effect is doomed to be acute and transient. However, in the case of MLN4924, the effect is rather long term; MLN4924 appears to break the dynamic balance of EGFR recycling by inducing dimerization, causing persistent transduction of hyperactivated EGFR signaling to stimulate sphere formation, which is a long-period process for up to 16 d. The involvement of activation of EGFR and its downstream pathways in MLN4924-induced TS stimulation was further confirmed by our rescue experiments with both a loss-of-function approach, which confirmed the involvement of EGFR and two of its main downstream pathways-PI3K/AKT/mTORC1 and MAPK (Table S1 )-and a gain-of-function approach, which confirmed the necessity of the kinase activity of EGFR.
However, another interesting observation we made here is that this TS-stimulating effect was only observed within a certain range of MLN4924 concentrations, mostly centering at 0.1 μM, which is sufficient to inhibit cullin-1 neddylation (Fig. 4B, Fig.  5A, and Fig. S5A ). The underlying mechanism of the opposing effects of MLN4924 in growth stimulation (at low concentration) versus growth suppression (at high concentration) is not clear at the present time. It is conceivable that MLN4924 facilitates chronic EGFR activation by inducing dimerization, particularly under serum-free condition, whereas higher concentration exhibited predominantly antiproliferation properties by causing accumulation of tumor suppressor proteins via blockage of their proteasomal degradation due to inactivation of CRL E3 ligases (56) . It is worth noting that MLN4924 concentrations of 0.1 μM are lower than peak plasma concentrations of ∼1.5 μM reached at the maximum tolerated dose of 59 mg/m 2 in a phase 1 trial of MLN4924 in AML and MDS (12) . Although the half-life of MLN4924 in mice was not measured directly, Soucy et al. (7) did show that the levels of NEDD8-cullin conjugate were reduced to 20% of the original within the first 2 h upon a single subcutaneous dose of MLN4924, and 50% levels of reduction were maintained for up to 24 h. On the other hand, the results of pK analysis for MLN4924 in patients were separately presented as abstracts by J. J. Shah during the 51st American Society of Hematology Annual Meeting and Exposition (57) and J. S. Kauh during the 2009 American Society of Clinical Oncology Annual Meeting (58), which indicated a half-life of 4-9 h and 5-15 h via intravenous infusion, respectively. Generally, the drug administered via local injection (as for the xenograft assays conducted in our study) could have a prolonged and concentrated effect in the injected areas compared with IV infusion. Nevertheless, our observation that MLN4924 possesses the proliferation-and spherestimulating activity at nanomolar concentration raises concern for its application in the treatment of human cancer (especially solid tumors), while suggesting a potential future application of MLN4924 in stem cell therapy and tissue regeneration.
The process of wound healing can be divided into three phases: (i) hemostasis and inflammation, (ii) proliferation/tissue formation, and (iii) tissue remodeling (59) . It is currently acknowledged that multiple types of stem cells reside within the dermis and epidermis, including stem cells in the interfollicular epidermis (IFE), and hair follicular stem cells and melanocyte stem cells in the hair follicle bulge (60) . Cells from both hair follicles and IFE migrate into the site of damage following full-thickness wound creation, contributing to wound repair (61), whereas only IFE plays a major role in wound reepithelialization (62) . Here we showed that in both in vivo and in vitro settings MLN4924 accelerated the EGF-induced skin wound healing process as well as epithelial cell migration. It is unclear why this early stage healing acceleration in our mouse model did not eventually translate to an overall shortening of the healing process. We speculate that MLN4924 may be only effective in the first two stages of wound healing by inhibiting inflammation (63) and promoting proliferation (this study) but not the last stage of tissue remodeling, which is a subject of future investigation. Nevertheless, the healing-accelerating and migration-promoting effects may benefit patients, particularly those with chronic skin wounds such as diabetic ulcers and large area of skin loss resulting from trauma or burns.
In summary, we made a surprising observation that blockage of the neddylation modification with low concentrations of MLN4924 significantly stimulates proliferation and sphere formation in human cancer cells and mESCs both in an in vitro cell culture setting and in vivo animal studies with a mechanism involving accumulation of c-Myc and chronic activation of EGFR via dimerization (Fig. 8) . Our study might pave the foundation for future development of MLN4924 as a novel class of agents for stem cell therapy and tissue regeneration.
Materials and Methods
Study Approval. All procedures and experiments were approved by the University of Michigan Committee for the Use and Care of Animals. Animal care was provided in accordance with the principles and procedures outlined in the National Research Council Guide for the Care and Use of Laboratory Animals (64) . The human cancer cell lines used in this study were purchased from ATCC and cultured according to the instructions provided.
Sphere Formation Assay. A single cancer cell suspension was made by enzymatic/mechanic disassociation, followed by filtration through a 40-μM cell strainer. Cells were washed in 1× DPBS (Dulbecco's phosphate-buffered saline) twice, counted, and plated at clonal density in TS conditioned medium, consisting of serum-free DMEM F12 supplemented with 0.4% BSA, 5 mM Hepes, penicillin/streptomycin, 20 ng/mL EGF (Life Technologies), and 10 ng/mL bFGF (Sigma), unless otherwise indicated, in 24-well ultra-low attachment (ULA) plates (Corning). SSSs are documented as previously described (16) EGFR Dimerization. H1299 and HCT116 cells were serum-starved for 24 h and then treated with 0.1 μM MLN4924 for 1 h or 24 h with the addition of 150 μM DSS, a cross-linking agent, in the last 30 min of treatment. For positive control, 30 ng/mL of EGF was added in combination with DSS and incubated for 30 min. Cells were scraped into RIPA buffer with protease inhibitor mixture (Roche Diagnostics). Cell lysates were then sonicated and centrifuged at 20,000 × g for 15 min at 4°C. The soluble protein fraction was collected and subjected to immunoblotting to detect EGFR dimerization.
In Situ PLA. A previous protocol (40) was followed with minor modification. Briefly, EGFR-null CHO cells were cotransfected with plasmids expressing EGFR-FLAG and EGFR-MYC. Twenty-four hours later, cells were seeded on coverslips and treated with 0.1 μM MLN4924 for 1 h or 24 h, respectively. For the positive control, 100 ng/mL of EGF was added and incubated for 30 min. The combination of MLN4924 and EGF was included. Cells were washed with ice-cold PBS, fixed, permeabilized, and incubated with mouse anti-MYC (Sigma-Aldrich) and rabbit anti-FLAG (Sigma-Aldrich) primary antibodies and then stained using Duolink In Situ-Fluorescence kit (Sigma-Aldrich), according to the manufacturer's recommendation. PLA images were collected and quantified by Duolink ImageTool.
Statistical Analysis. Statistical analyses were performed using paired or unpaired Student's t test or two-way ANOVA. Data were represented as mean ± SEM from at least three independent experiments or otherwise indicated. Not significant P > 0.05, *0.01 < P < 0.05, **0.005 < P < 0.01, ***P < 0.005. 
